TITLE

Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects

AUTHOR(S)
Poewe, W; Schelosky, L; Kleedorfer, B
PUB. DATE
February 1991
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Feb1991, Vol. 54 Issue 2, p186
SOURCE TYPE
Academic Journal
DOC. TYPE
letter
ABSTRACT
No abstract available.
ACCESSION #
66095845

 

Related Articles

  • Bromocriptine and Endocrine Disorders. Spark, Richard F.; Dickstein, Gabriel // Annals of Internal Medicine;Jun79, Vol. 90 Issue 6, p949 

    Presents information on bromocriptine, a dopaminergic agonist used to treat endocrine disorders. List of disorders treated with the drug; Background of endocrinology; Effects of serum proclatin values on patients with galactorrhea-amenorrhea syndrome after a single oral dose of bromocriptine.

  • Bromocriptine, a Dopamine (D2) Receptor Agonist, Used Alone and in Combination with Glipizide in Sub-Therapeutic Doses to Ameliorate Hyperglycaemia. HARISH KUMAR, V. S.; VINUTHA, M. B.; PRADEEP, A. N.; AITHAL, SATHISHA; BALEED, SINDHURA REDDY; PATIL, UMAKANT N. // Journal of Clinical & Diagnostic Research;Sep2013, Vol. 7 Issue 9, p1904 

    Introduction: Bromocriptine, an ergot derivative, is an agonist at the dopamine 2 receptor and a sympatholytic. It is a well established drug in Parkinsonism, hyperprolactinaemia and acromegaly and it has various other clinical indications like induction of ovulation in female infertility....

  • The Effect of Bromocriptine on the Disease Activity Index in Patients with Rheumatoid Arthritis. Salesi, Mansour; Haddadzavareh, Somayeh Sadeghi; Nasri, Peyman; Gharaghani, Nasrin Namdari; Farajzadegan, Ziba // Journal of Isfahan Medical School;June2011, Vol. 29 Issue 133, p344 

    Background: Limited studies have shown that the administration of Bromocriptine leads to clinical improvement in a number of rheumatic patients. Low price of Bromocriptine and its trivial side effects lead the authors to investigating the effect of Bromocriptine on rheumatoid arthritis (RA)...

  • Effect of repeated treatment with high doses of selegiline on behaviour, striatal dopaminergic transmission and tyrosine hydroxylase mRNA levels. Themann, C.; Alvarez Fischer, D.; Groß, S.; Westermann, R.; Weihe, E.; Kuschinsky, K.; Schäfer, M.; Ferger, B. // Naunyn-Schmiedeberg's Archives of Pharmacology;Jan2002, Vol. 365 Issue 1, p22 

    The anti-parkinsonian drug selegiline is a monoamine oxidase B (MAO-B) inhibitor and a potential neuroprotective agent which facilitates dopaminergic transmission. Its metabolites (-)-amphetamine and (-)-metamphetamine might contribute to the pharmacological effects as they are also able to...

  • Clinical Features and Medical Treatment of Male Prolactinomas. Asano, S.; Ueki, K.; Suzuki, I.; Kirino, T. // Acta Neurochirurgica;Jun2001, Vol. 143 Issue 5, p465 

    Summary Background. Prolactinomas found in male patients show distinct clinical features compared to those in female patients, which may warrant a different treatment strategy. Method. To clarify their clinical features and to evaluate the treatment results, specifically the results of surgical...

  • Bromocriptine, a Dopamine Agonist, Increases Growth Hormone Secretion in a Patient with Acromegaly. Zenei Arihara; Kanako Sakurai; Rika Yamashita; Satsuki Niitsuma; Takayuki Ueno; Nao Yamamura; Shozo Yamada; Naoko Inoshita; Kazuhiro Takahashi // Tohoku Journal of Experimental Medicine;Oct2014, Vol. 234 Issue 2, p129 

    Bromocriptine, a potent D2-dopamine agonist, suppresses growth hormone (GH) secretion in most patients with acromegaly and has been approved for the treatment of acromegaly. Here we report a patient with acromegaly who showed increased GH secretion after administration of bromocriptine. A...

  • Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study.  // BMJ: British Medical Journal (International Edition);6/8/91, Vol. 302 Issue 6789, p1367 

    Compares the efficacy and safety of single dose cabergoline versus bromocriptine in inhibiting puerperal lactation. Reduction on the rate of rebound breast activity; Decrease of serum prolactin concentration; Concerns on the administration schedule.

  • Effects of furosemide on low-dose mercuric chloride acute renal failure in the rat. Ufferman, Robert C.; Jaenike, John R.; Freeman, Richard B.; Pabico, Rufino C. // Kidney International;Dec1975, Vol. 8 Issue 6, p362 

    The use of potent diuretics in acute renal failure remains controversial. Both beneficial and detrimental effects have been reported. In the present study, the effects of both low and high doses of furosemide administered in the developmental and established stages of mercuric chloride-induced...

  • It Is Not What You Know That Gets You In Trouble, It Is What You Know That Is Not True. Davis, Neil M. // Hospital Pharmacy;Nov2009, Vol. 44 Issue 11, p935 

    The author emphasizes that the traditional way for administering oral colchicine to treat acute gout is no longer appropriate as of 2009. He cites a report stating that the U.S. Food and Drug Administration (FDA) has approved the Colcrys, the first oral colchicine product comprising of a...

  • Toxicological Evaluation of Murraya Paniculata (L.) Leaves Extract on Rodents. Gautam, M.K.; Singh, A.; Rao, C.V.; Goel, R.K. // American Journal of Pharmacology & Toxicology;2012, Vol. 7 Issue 2, p62 

    Problem statement: Present study was aimed to explore the acute and sub-acute toxicities studies with orally administered 50% ethanolic leaves extract of Murraya paniculata. Approach: Acute toxicity (oral single dose, 50-2000 mg kg-1) includes any mortality and CNS and ANS toxicities in mice...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics